Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy

JAMA Ophthalmology

Volumn 132, Issue 5, 2014, Pages 535-543

  Scott, Ingrid U ^a,b   Jackson, Gregory R ^a,c   Quillen, David A ^a   Larsen, Michael ^d,e   Klein, Ronald ^f   Liao, Jason ^b   Holfort, Stig ^d   Munch, Inger Christine ^e,g   Gardner, Thomas W ^h  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c MacuLogix Inc   (United States)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g ROSKILDE HOSPITAL   (Denmark)

^h UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DOXYCYCLINE; PLACEBO;

ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DARK ADAPTATION; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PERIMETRY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD VESSEL; RETINAL THICKENING; SIDE EFFECT; TRAFFIC ACCIDENT; TREATMENT DURATION; VISION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; VITREOUS HEMORRHAGE;

ADAPTATION, OCULAR; ADULT; AGED; ANTI-BACTERIAL AGENTS; CONTRAST SENSITIVITY; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEASIBILITY STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RETINA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VISUAL FIELD TESTS; VISUAL FIELDS; VITREORETINOPATHY, PROLIFERATIVE; YOUNG ADULT;

EID: 84900393461     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.93     Document Type: Article

References (54)

1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179-183.
2. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653-2664.
3. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ. 2006;333(7566):475-480.
4. Cheung N,Mitchell P,Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136.
5. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 87(1): 4-14.
6. YangW, Lu J,Weng J, et al; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090-1101.
7. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-1239.
8. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30(2):65-84.
9. Bhagat N, Grigorian RA, Tutela A, ZarbinMA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32.
10. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5): 343-358.
11. Rungger-Brandle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41(7):1971- 1980.
12. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17(3):463-471.
13. Zeng HY, Green WR, Tso MO.Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126(2):227-232.
14. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46(6):2210-2218.
15. Gaucher D, Chiappore JA, PaquesM, et al. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007;47(5):612-623.
16. Ibrahim AS, El-Remessy AB, Matragoon S, et al. Retinal microglial activation and inflammation induced by Amadori-glycated albumin in a rat model of diabetes. Diabetes. 2011;60(4):1122-1133.
17. Krady JK, Basu A, Allen CM, et al.Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54(5):1559-1565.
18. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1 signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007;56(1):224-230.
19. Wang AL, Yu AC, Lau LT, et al. Minocycline inhibits LPS-induced retinal microglia activation. Neurochem Int. 2005;47(1-2):152-158.
20. Federici TJ. The non-Antibiotic properties of tetracyclines: clinical potential in ophthalmic disease. Pharmacol Res. 2011;64(6):614-623.
21. Baptiste DC, Powell KJ, Jollimore CAB, et al. Effects ofminocycline and tetracycline on retinal ganglion cell survival after axotomy. Neuroscience. 2005;134(2):575-582.
22. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-Antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res. 2011;63(2):102-107.
23. Cukras CA, Petrou P, Chew EY,Meyerle CB, WongWT. Oralminocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci. 2012;53(7):3865-3874.
24. Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ. Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci. 2008;49(6):2635-2642.
25. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52(2):1156-1163.
26. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. J Clin Invest. 1998;102(4):783-791.
27. Jackson GR, Scott IU, Quillen DA,Walter LE, Gardner TW. Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy. Br J Ophthalmol. 2012;96(5):699-703.
28. van Dijk HW, Kok PH, GarvinM, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50(7):3404-3409.
29. van DijkHW, Verbraak FD, Kok PH, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51:3660-3665.
30. Takahashi H, Chihara E. Impact of diabetic retinopathy on quantitative retinal nerve fiber layer measurement and glaucoma screening. Invest Ophthalmol Vis Sci. 2008;49(2):687-692.
31. Parravano M, Oddone F, Mineo D, et al. The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. Br J Ophthalmol. 2008;92(12):1656-1660.
32. Parikh R, NaikM, Mathai A, Kuriakose T, Muliyil J, Thomas R. Role of frequency doubling technology perimetry in screening of diabetic retinopathy. Indian J Ophthalmol. 2006;54(1):17-22.
33. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88(7):583-600.
34. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978;85(1):82-106.
35. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-An extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology. 1991; 98(5)(suppl): 786-806.
36. Klein R, Klein BE, Magli YL, et al. An alternative method of grading diabetic retinopathy. Ophthalmology. 1986;93:1183-1187.
37. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology. 1991;98(suppl):823-833.
38. Klein BE, Davis MD, Segal P, et al. Diabetic retinopathy: assessment of severity and progression. Ophthalmology. 1984;91:10-17.
39. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. TheWisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497-503.
40. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
41. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vision Sci. 1988;2:187-199.
42. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD; NEI-VFQ Field Test Investigators. Psychometric properties of the National Eye Institute visual function questionnaire (NEI-VFQ). Arch Ophthalmol. 1998;116(11):1496- 1504.
43. Owsley C, McGwin G Jr., Scilley K, Kallies K. Development of a questionnaire to assess vision problems under low luminance in age-related maculopathy. Invest Ophthalmol Vis Sci. 2006;47(2):528-535.
44. Knudtson MD, Lee KE, Hubbard LD,Wong TY, Klein R, Klein BE. Revised formulas for summarizing retinal vessel diameters. Curr Eye Res. 2003;27(3):143-149.
45. Jackson GR, Barber AJ. Visual dysfunction associated with diabetic retinopathy. Curr Diab Rep. 2010;10(5):380-384.
46. James AC, Maddess T, Rouhan K, et al. Evidence forMy-cell involvement in the spatial frequency doubled illusion as revealed by multiple region PERG for glaucoma. J Opt Soc Am VSIA Techn Dig. 1995;1:314-317.
47. Maddess T, Hemmi JM, James AC. Evidence for spatial aliasing effects in the Y-like cells of the magnocellular visual pathway. Vision Res. 1998;38(12):1843-1859.
48. Jackson GR, Edwards JG. A short-duration dark adaptation protocol for assessment of age-related maculopathy. J Ocul Biol Dis Infor. 2008;1(1):7-11.
49. van den Bogert C, Kroon AM. Tissue distribution and effects onmitochondrial protein synthesis of tetracyclines after prolonged continuous intravenous administration to rats. Biochem Pharmacol. 1981;30(12):1706-1709.
50. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalianmitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother. 2006;50(6):2042-2049.
51. Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc Res. 2012;95(2): 173-182.
52. Klemp K, Sander B, Brockhoff PB, Vaag A, Lund-Andersen H, Larsen M. The multifocal ERG in diabetic patients without retinopathy during euglycemic clamping. Invest Ophthalmol Vis Sci. 2005;46(7):2620-2626.
53. Johnson LE, Larsen M, PerezMT. Retinal adaptation to changing glycemic levels in a rat model of type 2 diabetes. PLoS One. 2013;8(2):e55456. doi:10.1371/journal.pone.0055456.
54. Holfort SK, Norgaard K, Jackson GR, et al. Retinal function in relation to improved glycaemic control in type 1 diabetes. Diabetologia. 2011;54(7):1853-1861.